FDA approves GSK's Blujepa, a new oral antibiotic for uncomplicated UTIs, marking the first new class of antibiotics for this condition in nearly 30 years.
Shell to cut costs, focus on LNG and reduce clean energy investments, sparking criticism from activists.
FDA approves GSK's Blujepa, a new oral antibiotic for uncomplicated UTIs, marking the first new class of antibiotics for this condition in nearly 30 years.
Shell to cut costs, focus on LNG and reduce clean energy investments, sparking criticism from activists.